MicroVAX Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

MicroVAX General Information

Description

Operator of a clinical biotechnology company intended to develop a cancer vaccine. The company is dedicated to the development of potent vaccines, for treatment and preventive purposes, having applications in the areas of cancer and infectious diseases for which effective solutions have not yet been developed, enabling medical professionals to treat patients in a better way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly Angel backed
Corporate Office
  • 10900 Univesity Boulevard
  • Mason Enterprise Center MS 1J2
  • Manassas, VA 20110
  • United States
+1 (703)
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Services
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 10900 Univesity Boulevard
  • Mason Enterprise Center MS 1J2
  • Manassas, VA 20110
  • United States
+1 (703)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MicroVAX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private 01-Jan-2023 Completed Clinical Trials - Phase 1
2. Angel (individual) 13-Apr-2015 Completed Clinical Trials - Phase 1
1. Angel (individual) 22-Feb-2011 $22.5K $22.5K Completed Startup
To view MicroVAX’s complete valuation and funding history, request access »

MicroVAX Patents

  • 56

    Total Documents Applications and Grants

  • Total Patents Families

  • 30

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

MicroVAX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230241193-A1 Mrna vaccine design using multiple interacting immuno-stimulatory pathways, for cancer and infectious diseases Pending 03-Feb-2022
EP-4472660-A1 A mrna vaccine design using multiple interacting immuno-stimulatory pathways, for cancer and infectious diseases Pending 03-Feb-2022
US-20190070289-A1 Combination cancer therapy Active 01-Sep-2017
EP-3675891-A1 Combination cancer therapy Active 01-Sep-2017
CA-3073992-A1 Combination cancer therapy Pending 01-Sep-2017 A61K39/39558
To view MicroVAX’s complete patent history, request access »

Ready to get started?

Request a free trial

MicroVAX FAQs

  • When was MicroVAX founded?

    MicroVAX was founded in 2010.

  • Where is MicroVAX headquartered?

    MicroVAX is headquartered in Manassas, VA.

  • What industry is MicroVAX in?

    MicroVAX’s primary industry is Drug Discovery.

  • Is MicroVAX a private or public company?

    MicroVAX is a Private company.

  • What is MicroVAX’s current revenue?

    The current revenue for MicroVAX is .

  • How much funding has MicroVAX raised over time?

    MicroVAX has raised $320K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »